Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.

Curr Oncol Rep · 2022 · PMC9249697 · PMID 35366166

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

KEYNOTE-022 failed to reach significance at the pre-specified analysis but notably achieved a HR of 0.53 in the 36-month post hoc analysis, suggesting longer follow up is required to demonstrate the true benefit of triplet therapy compared to doublet therapy.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.